Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Ocular Infections, Irritations and Inflammations
Clinical Trial
NCT02163824Last updated: 12/4/2025
KALA
Kala Pharmaceuticals, Inc.
